Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1999 Nov;83(11):1230–1234. doi: 10.1136/bjo.83.11.1230

Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium

A DICK 1, J ISAACS 1
PMCID: PMC1722865  PMID: 10535846

Full Text

The Full Text of this article is available as a PDF (84.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arocker-Mettinger E., Steurer-Georgiew L., Steurer M., Huber-Spitzy V., Hoelzl E., Grabner G., Kuchar A. Circulating ICAM-1 levels in serum of uveitis patients. Curr Eye Res. 1992;11 (Suppl):161–166. doi: 10.3109/02713689208999527. [DOI] [PubMed] [Google Scholar]
  2. Ayliffe W., Alam Y., Bell E. B., McLeod D., Hutchinson I. V. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol. 1992 Oct;76(10):602–606. doi: 10.1136/bjo.76.10.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  4. Calder V. L., Zhao Z. S., Wang Y., Barton K., Lightman S. L. Effects of CD8 depletion on retinal soluble antigen induced experimental autoimmune uveoretinitis. Immunology. 1993 Jun;79(2):255–262. [PMC free article] [PubMed] [Google Scholar]
  5. Caspi R. R., Roberge F. G., McAllister C. G., el-Saied M., Kuwabara T., Gery I., Hanna E., Nussenblatt R. B. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986 Feb 1;136(3):928–933. [PubMed] [Google Scholar]
  6. Chanaud N. P., 3rd, Vistica B. P., Eugui E., Nussenblatt R. B., Allison A. C., Gery I. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res. 1995 Oct;61(4):429–434. doi: 10.1016/s0014-4835(05)80138-1. [DOI] [PubMed] [Google Scholar]
  7. Cobbold S. P., Adams E., Marshall S. E., Davies J. D., Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev. 1996 Feb;149:5–33. doi: 10.1111/j.1600-065x.1996.tb00897.x. [DOI] [PubMed] [Google Scholar]
  8. Cobbold S. P., Qin S., Leong L. Y., Martin G., Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev. 1992 Oct;129:165–201. doi: 10.1111/j.1600-065x.1992.tb01423.x. [DOI] [PubMed] [Google Scholar]
  9. Cope A. P. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998 Dec;10(6):669–676. doi: 10.1016/s0952-7915(98)80087-3. [DOI] [PubMed] [Google Scholar]
  10. Crane I. J., Kuppner M. C., McKillop-Smith S., Knott R. M., Forrester J. V. Cytokine regulation of RANTES production by human retinal pigment epithelial cells. Cell Immunol. 1998 Feb 25;184(1):37–44. doi: 10.1006/cimm.1997.1235. [DOI] [PubMed] [Google Scholar]
  11. De Vos A. F., Van Haren M. A., Verhagen C., Hoekzema R., Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res. 1995 Dec;61(6):667–675. doi: 10.1016/s0014-4835(05)80017-x. [DOI] [PubMed] [Google Scholar]
  12. Dick A. D., Azim M., Forrester J. V. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol. 1997 Dec;81(12):1107–1112. doi: 10.1136/bjo.81.12.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dick A. D., Cheng Y. F., Purdie A. T., Liversidge J., Forrester J. V. Immunocytochemical analysis of blood lymphocytes in uveitis. Eye (Lond) 1992;6(Pt 6):643–647. doi: 10.1038/eye.1992.138. [DOI] [PubMed] [Google Scholar]
  14. Dick A. D., Ford A. L., Forrester J. V., Sedgwick J. D. Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b/c+CD4low parenchymal microglia. Br J Ophthalmol. 1995 Sep;79(9):834–840. doi: 10.1136/bjo.79.9.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dick A. D., Kreutzer B., Laliotou B., Forrester J. V. Effects of mycophenolate mofetil on nasal mucosal tolerance induction. Invest Ophthalmol Vis Sci. 1998 Apr;39(5):835–840. [PubMed] [Google Scholar]
  16. Dick A. D., McMenamin P. G., Körner H., Scallon B. J., Ghrayeb J., Forrester J. V., Sedgwick J. D. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996 May;26(5):1018–1025. doi: 10.1002/eji.1830260510. [DOI] [PubMed] [Google Scholar]
  17. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  18. Feron E. J., Calder V. L., Lightman S. L. Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. Curr Eye Res. 1992;11 (Suppl):167–172. doi: 10.3109/02713689208999528. [DOI] [PubMed] [Google Scholar]
  19. Forrester J. V. Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye (Lond) 1992;6(Pt 5):433–446. doi: 10.1038/eye.1992.93. [DOI] [PubMed] [Google Scholar]
  20. Forrester J. V., Liversidge J., Dua H. S., Towler H., McMenamin P. G. Comparison of clinical and experimental uveitis. Curr Eye Res. 1990;9 (Suppl):75–84. doi: 10.3109/02713689008999424. [DOI] [PubMed] [Google Scholar]
  21. Forrester J. V., McMenamin P. G., Holthouse I., Lumsden L., Liversidge J. Localization and characterization of major histocompatibility complex class II-positive cells in the posterior segment of the eye: implications for induction of autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):64–77. [PubMed] [Google Scholar]
  22. GORDON D. M. Prednisone and prednisolone in ocular disease. Am J Ophthalmol. 1956 Apr;41(4):593–600. [PubMed] [Google Scholar]
  23. Guex-Crosier Y., Raber J., Chan C. C., Kriete M. S., Benichou J., Pilson R. S., Kerwin J. A., Waldmann T. A., Hakimi J., Roberge F. G. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997 Jan 1;158(1):452–458. [PubMed] [Google Scholar]
  24. Gupta D., Singh V. K., Rajasingh J., Shinohara T., Misra R., Agarwal S. S. Cellular immune responses of patients with juvenile chronic arthritis to retinal antigens and their synthetic peptides. Immunol Res. 1996;15(1):74–83. doi: 10.1007/BF02918285. [DOI] [PubMed] [Google Scholar]
  25. He Y., Mellon J., Apte R., Niederkorn J. Y. Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3218–3225. [PubMed] [Google Scholar]
  26. Higuchi M., Diamantstein T., Osawa H., Caspi R. R. Combined anti-interleukin-2 receptor and low-dose cyclosporine therapy in experimental autoimmune uveoretinitis. J Autoimmun. 1991 Feb;4(1):113–124. doi: 10.1016/0896-8411(91)90011-z. [DOI] [PubMed] [Google Scholar]
  27. Hori J., Isobe M., Yamagami S., Tsuru T. Acceptance of second corneal allograft by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Transplant Proc. 1998 Feb;30(1):200–201. doi: 10.1016/s0041-1345(97)01230-x. [DOI] [PubMed] [Google Scholar]
  28. Hori J., Yamagami S., Obata H., Tsuru T., Isobe M. Effect of monoclonal antibody to VLA-4 on corneal allograft survival in mice. Transplant Proc. 1996 Jun;28(3):1990–1991. [PubMed] [Google Scholar]
  29. Hossain P., Liversidge J., Cree M. J., Manivannan A., Vieira P., Sharp P. F., Brown G. C., Forrester J. V. In vivo cell tracking by scanning laser ophthalmoscopy: quantification of leukocyte kinetics. Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1879–1887. [PubMed] [Google Scholar]
  30. Howe L. J., Stanford M. R., Edelsten C., Graham E. M. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye (Lond) 1994;8(Pt 4):443–447. doi: 10.1038/eye.1994.105. [DOI] [PubMed] [Google Scholar]
  31. Isaacs J. D., Burrows N., Wing M., Keogan M. T., Rebello P. R., Watts R. A., Pye R. J., Norris P., Hazelman B. L., Hale G. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol. 1997 Nov;110(2):158–166. doi: 10.1111/j.1365-2249.1997.tb08312.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Isaacs J. D., Greenwood J., Waldmann H. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol. 1998 Oct 15;161(8):3862–3869. [PubMed] [Google Scholar]
  33. Isaacs J. D., Hale G., Waldmann H., Dick A. D., Haynes R., Forrester J. V., Watson P., Meyer P. A. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol. 1995 Nov;79(11):1054–1055. doi: 10.1136/bjo.79.11.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Isaacs J. D., Manna V. K., Rapson N., Bulpitt K. J., Hazleman B. L., Matteson E. L., St Clair E. W., Schnitzer T. J., Johnston J. M. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol. 1996 Mar;35(3):231–240. doi: 10.1093/rheumatology/35.3.231. [DOI] [PubMed] [Google Scholar]
  35. Isaacs J. D., Waldmann H. Regaining self-control--regulation and immunotherapy. Br J Rheumatol. 1998 Sep;37(9):926–929. doi: 10.1093/rheumatology/37.9.926. [DOI] [PubMed] [Google Scholar]
  36. Isaacs J., Dick A. Short term immunosuppressive therapy and long-term immunoregulation: promises and problems. Br J Ophthalmol. 1996 Dec;80(12):1035–1036. doi: 10.1136/bjo.80.12.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ishioka M., Ohno S., Nakamura S., Isobe K., Watanabe N., Ishigatsubo Y., Tanaka S. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994 Dec 15;118(6):723–729. doi: 10.1016/s0002-9394(14)72551-6. [DOI] [PubMed] [Google Scholar]
  38. Jabs D. A., Prendergast R. A. Autoimmune ocular disease in MRL/Mp-lpr/lpr mice is suppressed by anti-CD4 antibody. Invest Ophthalmol Vis Sci. 1991 Sep;32(10):2718–2722. [PubMed] [Google Scholar]
  39. Kasner L., Chan C. C., Whitcup S. M., Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1993 Sep;34(10):2911–2917. [PubMed] [Google Scholar]
  40. Khoury S. J., Akalin E., Chandraker A., Turka L. A., Linsley P. S., Sayegh M. H., Hancock W. W. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15;155(10):4521–4524. [PubMed] [Google Scholar]
  41. Kilmartin D. J., Forrester J. V., Dick A. D. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998 Jul 4;352(9121):35–36. doi: 10.1016/S0140-6736(05)79515-5. [DOI] [PubMed] [Google Scholar]
  42. Kuppner M. C., Liversidge J., McKillop-Smith S., Lumsden L., Forrester J. V. Adhesion molecule expression in acute and fibrotic sympathetic ophthalmia. Curr Eye Res. 1993 Oct;12(10):923–934. doi: 10.3109/02713689309020399. [DOI] [PubMed] [Google Scholar]
  43. Larkin G., Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999 Feb;106(2):370–374. doi: 10.1016/S0161-6420(99)90078-7. [DOI] [PubMed] [Google Scholar]
  44. Lenschow D. J., Ho S. C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K. C., Bluestone J. A. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 Mar 1;181(3):1145–1155. doi: 10.1084/jem.181.3.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lockwood C. M., Thiru S., Stewart S., Hale G., Isaacs J., Wraight P., Elliott J., Waldmann H. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996 Dec;89(12):903–912. doi: 10.1093/qjmed/89.12.903. [DOI] [PubMed] [Google Scholar]
  46. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  47. Moreau T., Thorpe J., Miller D., Moseley I., Hale G., Waldmann H., Clayton D., Wing M., Scolding N., Compston A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994 Jul 30;344(8918):298–301. doi: 10.1016/s0140-6736(94)91339-0. [DOI] [PubMed] [Google Scholar]
  48. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  49. Murray P. I., Young D. W. Soluble interleukin-2 receptors in retinal vasculitis. Curr Eye Res. 1992;11 (Suppl):193–195. doi: 10.3109/02713689208999532. [DOI] [PubMed] [Google Scholar]
  50. Neuberger M. S., Williams G. T., Fox R. O. Recombinant antibodies possessing novel effector functions. Nature. 1984 Dec 13;312(5995):604–608. doi: 10.1038/312604a0. [DOI] [PubMed] [Google Scholar]
  51. Newman D. K., Isaacs J. D., Watson P. G., Meyer P. A., Hale G., Waldmann H. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye (Lond) 1995;9(Pt 5):564–569. doi: 10.1038/eye.1995.140. [DOI] [PubMed] [Google Scholar]
  52. Nussenblatt R. B., Rodrigues M. M., Wacker W. B., Cevario S. J., Salinas-Carmona M. C., Gery I. Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest. 1981 Apr;67(4):1228–1231. doi: 10.1172/JCI110138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pleyer U., Milani J. K., Dukes A., Chou J., Lutz S., Rückert D., Thiel H. J., Mondino B. J. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci. 1995 Jan;36(1):52–61. [PubMed] [Google Scholar]
  54. Ramanathan S., de Kozak Y., Saoudi A., Goureau O., Van der Meide P. H., Druet P., Bellon B. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J Immunol. 1996 Sep 1;157(5):2209–2215. [PubMed] [Google Scholar]
  55. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  57. Rothova A., Suttorp-van Schulten M. S., Frits Treffers W., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332–336. doi: 10.1136/bjo.80.4.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sainz de la Maza M., Foster C. S., Jabbur N. S. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995 Apr;102(4):687–692. doi: 10.1016/s0161-6420(95)30970-0. [DOI] [PubMed] [Google Scholar]
  59. Sartani G., Silver P. B., Rizzo L. V., Chan C. C., Wiggert B., Mastorakos G., Caspi R. R. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2211–2218. [PubMed] [Google Scholar]
  60. Saxena S., Rajasingh J., Biswas S., Kumar D., Shinohara T., Singh V. K. Cellular immune response to retinal S-antigen and interphotoreceptor retinoid-binding protein fragments in Eales' disease patients. Pathobiology. 1999;67(1):39–44. doi: 10.1159/000028049. [DOI] [PubMed] [Google Scholar]
  61. Shizuru J. A., Taylor-Edwards C., Banks B. A., Gregory A. K., Fathman C. G. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988 Apr 29;240(4852):659–662. doi: 10.1126/science.2966437. [DOI] [PubMed] [Google Scholar]
  62. Smith J. R., Hart P. H., Coster D. J., Williams K. A. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1998 Mar;39(3):658–661. [PubMed] [Google Scholar]
  63. Smith J. R., Hart P. H., Parish C. R., Standfield S. D., Coster D. J., Williams K. A. Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Clin Exp Immunol. 1999 Jan;115(1):64–71. doi: 10.1046/j.1365-2249.1999.00765.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Sugi-Ikai N., Nakazawa M., Nakamura S., Ohno S., Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci. 1998 May;39(6):996–1004. [PubMed] [Google Scholar]
  66. Suttorp-Schulten M. S., Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996 Sep;80(9):844–848. doi: 10.1136/bjo.80.9.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Tarrant T. K., Silver P. B., Wahlsten J. L., Rizzo L. V., Chan C. C., Wiggert B., Caspi R. R. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med. 1999 Jan 18;189(2):219–230. doi: 10.1084/jem.189.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Thurau S. R., Wildner G., Reiter C., Riethmüller G., Lund O. E. Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report. Ger J Ophthalmol. 1994 Nov;3(6):409–413. [PubMed] [Google Scholar]
  69. Uchio E., Kijima M., Tanaka S., Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci. 1994 Apr;35(5):2626–2631. [PubMed] [Google Scholar]
  70. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998 Jan 15;338(3):161–165. doi: 10.1056/NEJM199801153380304. [DOI] [PubMed] [Google Scholar]
  71. Wetzig R., Hooks J. J., Percopo C. M., Nussenblatt R., Chan C. C., Detrick B. Anti-Ia antibody diminishes ocular inflammation in experimental autoimmune uveitis. Curr Eye Res. 1988 Aug;7(8):809–818. doi: 10.3109/02713688809033212. [DOI] [PubMed] [Google Scholar]
  72. Whitcup S. M., Hikita N., Shirao M., Miyasaka M., Tamatani T., Mochizuki M., Nussenblatt R. B., Chan C. C. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res. 1995 Jun;60(6):597–601. doi: 10.1016/s0014-4835(05)80001-6. [DOI] [PubMed] [Google Scholar]
  73. Whitcup S. M., Kozhich A. T., Lobanoff M., Wolitzky B. A., Chan C. C. Blocking both E-selectin and P-selectin inhibits endotoxin-induced leukocyte infiltration into the eye. Clin Immunol Immunopathol. 1997 Apr;83(1):45–52. doi: 10.1006/clin.1996.4324. [DOI] [PubMed] [Google Scholar]
  74. Whitcup S. M., Pleyer U., Lai J. C., Lutz S., Mochizuki M., Chan C. C. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm. 1998 Mar;6(1):51–56. doi: 10.1076/ocii.6.1.51.8079. [DOI] [PubMed] [Google Scholar]
  75. Whitcup S. M., Vistica B. P., Magone M. T., George R. K. Elevated serum levels of soluble ICAM-1 in uveitis patients predict underlying systemic disease. Br J Ophthalmol. 1999 Feb;83(2):252–253. doi: 10.1136/bjo.83.2.252a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Winter G., Milstein C. Man-made antibodies. Nature. 1991 Jan 24;349(6307):293–299. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  77. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Wraith D. C., McDevitt H. O., Steinman L., Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989 Jun 2;57(5):709–715. doi: 10.1016/0092-8674(89)90786-1. [DOI] [PubMed] [Google Scholar]
  79. Yamagami S., Obata H., Tsuru T., Isobe M. Suppression of corneal allograft rejection after penetrating keratoplasty by antibodies to ICAM-1 and LFA-1 in mice. Transplant Proc. 1995 Apr;27(2):1899–1900. [PubMed] [Google Scholar]
  80. Yamamoto J. H., Minami M., Inaba G., Masuda K., Mochizuki M. Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. Br J Ophthalmol. 1993 Sep;77(9):584–589. doi: 10.1136/bjo.77.9.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Yokoi H., Kato K., Kezuka T., Sakai J., Usui M., Yagita H., Okumura K. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol. 1997 Mar;27(3):641–646. doi: 10.1002/eji.1830270310. [DOI] [PubMed] [Google Scholar]
  82. Zaman A. G., Edelsten C., Stanford M. R., Graham E. M., Ellis B. A., Direskeneli H., D'Cruz D. P., Hughes G. R., Dumonde D. C., Wallace G. R. Soluble intercellular adhesion molecule-1 (sICAM-1) as a marker of disease relapse in idiopathic uveoretinitis. Clin Exp Immunol. 1994 Jan;95(1):60–65. doi: 10.1111/j.1365-2249.1994.tb06015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. de Smet M. D., Yamamoto J. H., Mochizuki M., Gery I., Singh V. K., Shinohara T., Wiggert B., Chader G. J., Nussenblatt R. B. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol. 1990 Aug 15;110(2):135–142. doi: 10.1016/s0002-9394(14)76981-8. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES